Pathologic responses in oligometastatic NSCLC patients treated with neoadjuvant immune checkpoint blockade with and without chemotherapy followed by surgery

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations

Medicine, Oncology, Treatment Planning +14

Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non–Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study

Daniel R. Gomez, Chad Tang, Jianjun Zhang et al. · Journal of Clinical Oncology · 2019 · 1.3K citations · Full text

Medicine, Oncology, Surgery +15

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%

Martin Reck, Delvys Rodríguez‐Abreu, Andrew Robinson et al. · Journal of Clinical Oncology · 2021 · 1.1K citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease

Jing Liu, Stephen J. Blake, Michelle C.R. Yong et al. · Cancer Discovery · 2016 · 864 citations

Medicine, Immunology, Oncology +15

SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non–Small-Cell Lung Cancer—A Multicenter Single-Arm Phase II Trial

Sacha I. Rothschild, Alfred Zippelius, E.I. Eboulet et al. · Journal of Clinical Oncology · 2021 · 341 citations

Medicine, Oncology, Pharmacotherapy +13